1
. Vesicular systems such as liposomes and niosomes are promising systems to enhance the drug delivery through the skin. They may act as vehicles or as permeation enhancers for drugs to enhance their penetration via stratum corneum. Furthermore, they can be used as controlled percutaneous drug delivery vehicles. The applicability of these vesicular systems is, however, limited because of their stability problems. To overcome the limitations of vesicular drug delivery, proniosomal approach was introduced, which involved a dry product or a liquid crystalline gel that could be hydrated immediately before use and would avoid many of the problems associated with niosomal dispersion and problems of physical stability. Proniosomes are nonionic based surfactant vesicles used to enhance drug delivery in addition to conventional niosomes. There are a number of formulation approaches to resolve the problems of low solubility and low bioavailability. Proniosome technology offers novel solution for poorly soluble drugs Candesartan cilexetil (CC) is an esterified prodrug of candesartan, a non-peptide angiotensin II receptor antagonist used in the treatment of hypertension. This medication is also used to treat congestive heart failure. This drug may also be used to help protect the kidneys from damage due to diabetes. The major drawback in the therapeutic application and efficacy of Candesartan cilexetil as an oral dosage form is its very low aqueous solubility (0.003 mg/mL) and very low oral bioavailability i.e. only 15% 3 .
Some efforts have been made to enhance the solubility of candesartan cilexetil to study its effect on the bioavailability of the drug. A self emulsifying drug delivery systems (SEDDS) have been developed by M. Sunitha Reddy et al 4 to enhance the solubility, diffusion rate and oral bioavailability of candesartan cilexetil. The solubility of candesartan cilexetil in different media Tween 80, Sodium dodecyl sulfate, Macrogol 6000, Sodium carboxymethyl cellulose and Sodium carboxymethyl dextran has been reported by Eliska Vaculikova et al
.Fast dissolving tablets of

ABSTRACT:
The present work deals with the preparation of candesartan cilexetil proniosomal gel by coaservation phase separation method by using different surfactants, cholesterol and soya lecithin in 9:1:9 and 9:2:9 ratios. The prepared proniosomal gel formulations were evaluated for vesicle size analysis, surface morphological studies, encapsulation efficiency, In vitro drug release, ex vivo skin permeation studies and vesicular stability at different storage conditions. The results showed that candesartan cilexetil in all the formulations was successfully entrapped and a substantial change in release rate and an alteration in the encapsulation efficiency of candesartan cilexetil from proniosomes were observed upon varying the type of surfactant and cholesterol content. Vesicles formed with Spans were smaller in size than vesicles formed with Tweens. Encapsulation efficiency of proniosomes formed from Span 60, Span 40, Span20, and Span 80 was found high compared with proniosomes prepared from Tweens (Tween 20 and Tween 80). An optimised preparation with 9:2:9 ratio of Span 60, cholesterol and lecithin gave maximum encapsulation efficiency (92.29%) and showed drug release (95.89±0.26%) in a controlled manner with a flux value of 1.89 μg/cm 2 /hr and permeability co efficient value of 0.094 cm 2 /hr as compared to other compositions. No significant changes in relation to vesicle size and encapsulation efficiency were recorded after stability studies. It is evident from this study that proniosomes are a promising prolonged delivery system for candesartan cilexetil and have reasonably good stability characteristics. Keywords: candesartan cilexetil, proniosomes, encapsulation efficiency, flux, stability.
Candesartan cilexetil by using Novel co-processed superdisintegrants have been developed by S.B. Shirsand et al 6 to increase the solubility and dissolution rate of drug.
The aim of this study is to investigate the feasibility of formulation of proniosomes of Candesartan cilexetil. Vesicles prepared were characterized by optical, scanning electron microscopy for vesicle formation and morphology. Drug encapsulation efficiency and release studies were carried out. Finally, a stability study of proniosomal formulations was also performed to investigate the leaking of the drug during storage. 
MATERIALS AND METHODS:
Materials
Drug -Excipients Compatability studies by FT-IR spectroscopy
Fourier-transform infrared (FTIR) spectrophotometer was used for infra-red analysis of samples to interpret the interactions of drug with non-ionic surfactants and other ingredients. The powdered samples were used for FTIR studies. Infrared (IR) spectra were obtained on a Bruker 1.2.4 IR system (software OPUS 7.0) using the Attenuated Total Reflectance Spectroscopy method. The scanning range was 400-4000 cm-1. The FT-IR spectra of drug with Non-ionic surfactants,soya lecithin and cholesterol blends were compared with the FT-IR spectrum of pure drug.
Solubility studies
The solubility of Candesartan cilexetil was determined in water and different pH buffers (phosphate buffer of pH 6.5, pH 6.8 and pH 7.4) and phosphate buffer of pH 6.5 containing different amount of solubilizer (0.3%, 0.35%, 0.4%, 0.5% and 0.7% tween20) and the results revealed that, solubility of Candesartan cilexetil was more in phosphate buffer of pH 6.5 containing 0.35% tween20.
Preparation of Transdermal proniosomal gel
Proniosomal gel of candesartan cilexetil was prepared by coacervation phase separation technique. Drug and required quantities of materials viz surfactant, soya lecithin and cholesterol as per the specified ratio were taken in a dry, clean, wide mouthed test tube. A measured amount of ethanol (absolute alcohol) was added to test tube to dissolve the ingredients. The open end of test tube was covered with a lid to prevent loss of solvent from it and warmed over water bath at 60-70 0 C for about 5 minute until the surfactant mixture was dissolved completely. Then the aqueous phase (phosphate buffer of pH 6.5 containing 0.35% tween 20) was added and warmed on a water bath till a clear solution was formed. The clear solution formed was cooled to room temperature to convert it to a gel known as Proniosomal gel. The gel obtained was preserved in the same glass tube in a dark for characterization 7 .Composition of proniosomal gel formulations were given in Table 1 . Span 60(mg) 
Characterization of Proniosomal gel
Physical appearance of proniosomal gel 8 The prepared gel was viewed through naked eye to characterize color and physical state of gel. Proniosomal gel was also viewed by optical microscope at 40 X magnification, to observe crystal characteristics of gel by spreading as a thin layer on a slide and placing the cover slip on it. The appearance of each formulation was checked for its color, consistency and fluidity.
Vesicle Size Analysis 9
Size and size distribution studies were done for niosomes obtained after hydration of proniosomal gel with agitation (shaking) and without agitation. Size analysis was done by adding 10ml of phosphate buffer of pH 6.5 containing 0.35% tween 20 to the proniosomal gel (100mg) in a small glass vial with occasional shaking for 10 min. After hydration, the dispersion of niosomes was observed under optical microscope at 40x magnification. The sizes of 100 vesicles were measured using a calibrated ocular and stage micrometer fitted in a optical microscope.
Vesicle morphology 10
Shape and surface morphology of proniosomes was studied using scanning electron microscopy (SEM). The niosomes formed from the hydration of proniosomal gel were mounted on an aluminum stub with double-sided adhesive carbon tape. The vesicles were then sputter-coated with gold/palladium using a vacuum evaporator and examined with the scanning electron microscope equipped with a digital camera at 10kV accelerating voltage. pH determination 11 The proniosomal gel was made into niosomal suspension. Then the pH of niosomal suspension was determined using pH meter. 12 Proniosomal gel (0.2 g) was reconstituted with 10 ml of phosphate buffer of pH 6.5 containing 0.35% tween 20 in a glass tube. The aqueous suspension was sonicated in a bath sonicator for 15 min. The candesartan cilexetil containing niosomes were separated from unentrapped drug by centrifugation at 15000 rpm at 20°C for 90 min. The supernatant was taken and diluted with phosphate buffer of pH 6.5 containing 0.35% tween20 and the free drug concentration in the resulting solution was assayed by UV spectroscopic method at 257nm. The percentage of drug encapsulation was calculated by using the following equation.
Drug encapsulation efficiency determination
EP (%) = [(c t -c r )/c t ] × 100
Where EP is the encapsulation percentage, Ct is the concentration of total drug, and Cr is the concentration of free drug.
In-Vitro drug diffusion study 13 The in-vitro release studies on proniosomal gel were performed using Franz-diffusion cell. The capacity of receptor compartment was 10 ml. The area of donor compartment exposed to receptor compartment was 1.88 cm 2 . The membrane was mounted between the donor and receptor compartment. A weighed amount of proniosomal gel equivalent to 20mg drug was placed on one side of the membrane. 10 ml of phosphate buffer of pH 6.5 containing 0.35% tween 20 was taken as receptor medium. The receptor compartment was surrounded by a water jacket to maintain the temperature at 37±1ºC. The receptor fluid was stirred by a Teflon-coated magnetic bead fitted to a magnetic stirrer at a speed of 600 rpm. Samples were withdrawn at regular intervals (  1, 2, 3, 4,5, 6,7, 8,9, 10, 11, 12 , and 24 h). At each sampling interval, 1 ml samples were withdrawn and were replaced by equal volumes of fresh receptor fluid. Sink condition was maintained throughout the experiment. Samples withdrawn were suitably diluted and analyzed spectrophotometrically at 257 nm.
Release kinetics 14
To study the release kinetics, data obtained from in vitro diffusion studies was fitted in various kinetic models: zero order as cumulative percent of drug release vs. time, first order as log cumulative percentage of drug remaining vs. time, Higuchi's model as cumulative percent of drug release vs. square root of time and Erosion model as cubic root of the unreleased fraction of the drug versus time. To determine the mechanism of drug release, the data was fitted into Korsmeyer and Peppas equation as log cumulative percentage of drug released vs. log time, and the exponent n was calculated from slope of the straight line. The value of n characterizes the release mechanism of drug, if exponent is 0.5, then diffusion mechanism is fickian; if 0.5< n <0.89, mechanism is non-fickian, n = 1 to Case II (relaxational) transport, and n > 1 to super case II transport.
Preparation of wistar rat skin for permeation studies 1,11,15
In the present study, wistar albino rat abdominal skin was used. Ex vivo skin permeation studies were carried out with Institutional Animal Ethical Committee approval (Approval Number: HCOP/IAEC/2013-14/01). After the animal was sacrificed, the abdominal skin was shaved lightly with an electrical clipper (before of which a depilatory cream was applied) taking care to prevent any damage to the surface of the skin, then the abdominal skin was excised from the animal using a sharp blade and surgical scissors. The skin was lifted easily from the animal after incision was made. The skin was defatted by wiping it with a cotton tip soaked in diethyl ether to remove the subcutaneous fat and scraping the dermal side to remove the muscle and blood vessels. The skin was wiped again with a cotton tip soaked in ether to prevent any adhering fat. The skin so prepared was wrapped in aluminium foil and stored in a deep freezer at (2-5°C) till further use. The skin was defrosted at room temperature when required.
Ex-Vivo drug permeation studies
The selected formulations on the basis of entrapment efficiency, and in vitro drug release were subjected to permeation studies through rat skin using Franz Diffusion cell. Before starting the experiment, the skin was kept in phosphate buffer pH 7.4 for about 1 hour in a water bath at constant temperature of 37 ºC to allow water soluble UV absorbing material to leach out. The effective permeation area of the diffusion cell was 1.88 cm 2 . 10 ml of phosphate buffer of pH 6.5 containing 0.35% tween 20 was taken as receptor medium. Excised skin was mounted between the donor and the receptor compartment with stratum corneum side facing upwards into the donor compartment. The donor compartment was left open and wrapped with cellophane to prevent contamination of the formulation from the atmosphere, A weighed amount of proniosomal gel equivalent to 20mg drug was placed on the surface of the skin. Temperature was maintained at 37±1ºC using water bath. The receptor chamber contents were magnetically stirred at 600 rpm. Samples were withdrawn at regular intervals (1, 2, 3, 4,5, 6, 7,8, 9,10, 11,12 , and 24 h), and analyzed for drug content spectrophotometrically at 257 nm. Cumulative amount of drug permeated through the skin (µg/cm 2 ) was plotted as a function of time (t) for each formulation.
The skin flux (J)(μg/cm 2 /h),was determined from the slope of linear portion of the cumulative amount permeated per unit area versus the time plot. Permeability coefficient (Kp) (cm/h), was calculated by dividing J with the concentration of the drug in donor cell (C 0 ) by using the following equation:
The skin flux can be experimentally determined from the following equation J = (dQ/dt) /A where J is flux (μg/cm 2 per h), A: Area of skin tissue (cm 2 ) through which drug permeation takes place, (dQ/dt) is the slope. 16 Stability studies were conducted for the best formulation i.e. PNF7 of candesartan cilexetil proniosomal gel. The ability of vesicles to retain the drug (Drug Retention Behaviour) was assessed by keeping the proniosomal gel at three different temperature conditions, i.e., refrigeration temperature (4-8 0 C), room temperature (25±2 0 C) and oven maintained at (45±2 0 C). Throughout the study, proniosomal formulation was stored in aluminium foil-sealed glass vials.
Short term stability studies
The stored formulation was analyzed for particle size & percent drug entrapment.
RESULTS AND DISCUSSIONS
Drug -Excipients Compatability studies
The FTIR spectra of pure candesartan cilexetil and physical mixture of drug with excipient is shown in Fig.  1 (C-O-C) were characteristic to the pure candesartan cilexetil. IR spectrum of physical mixture of drug with excipients revealed that there was no appreciable change in position and intensity of peak with respect to IR spectrum of pure candesartan cilexetil. IR analysis revealed that there was no known chemical interaction between drug and excipients. 
Vesicle morphology
The morphology of niosomes derived from proniosomal gel was studied using Scanning Electron Microcopy. SEM imaging of candesartan cilexetil revealed that the niosomes produced from hydration of proniosomes were spherical in shape and discrete with sharp boundaries having large internal aqueous space. SEM imaging of niosome produced from optimized formulation PNF7 was shown in Fig 2. The optical microscopy images of the niosomes prepared from different proniosomal formulations are shown in Fig 3. (a) (b) Table 2 .
Vesicle size analysis
Mean Vesicle size of candesartan cilexetil proniosomes was presented in Table 2 , which indicated that vesicles formed with Spans were smaller in size than vesicles formed with Tweens. The relationship observed between niosome size and Span hydrophobicity has been attributed to the decrease in surface energy with increasing hydrophobicity, resulting in the smaller vesicles. This would also explain the large vesicle size of niosomes prepared with Tween which has a much lower hydrophobicity than Span. Increasing the cholesterol content also contributed an increase in the hydrophobicity, with a subsequent slight reduction in vesicle size. The differences in vesicle size among the niosomes prepared with Span were not significant. The Size of vesicle was reduced when dispersion was agitated due to breakage of larger vesicles to smaller vesicles.
pH determination
Skin compatibility is the primary requirement for a good topical formulation. It was found that the pH of all the formulations were in the range of 5.64 to 7.20, which suits the skin pH, indicating skin compatibility. The results of pH determination are reported in Table  2 .
Drug encapsulation efficiency
Encapsulation efficiency of proniosomal gel formulations ranged from 80.40% to 92.20%. The drug encapsulation efficiency of twelve formulations were shown in Table 2 .and As shown in Table 2 , Encapsulation efficiency of proniosomes formed from Span 60, Span 40, Span20, and Span 80 was found high compared with proniosomes prepared from Tweens (Tween 20, Tween 80). Among the spans, Span 60 have higher encapsulation efficiency due to the longer saturated alkyl chain compared to that of span 40,span 20 and span 80.Most of the surfactants used to make nonionic surfactant vesicles such as spans have a low aqueous solubility. However, freely soluble nonionic surfactants such as Tween can form the micelles on hydration in the presence of cholesterol. The tween formulations in the present study were also able to entrap candesartan cilexetil efficiently. However the encapsulation efficiency was relatively low compared to those composed of Span. This is because the vesicles can be successfully formed by Tween only in the presence of excess cholesterol.
As the cholesterol content of the formulation increased, the encapsulation of drug also increased. The formulations (PNF7-PNF12) containing 9:9:2 ratio of surfactant : soya lecithin : cholesterol showed high encapsulation efficiency compared to the formulations (PNF1-PNF6) containing 9:9:1 ratio of surfactant:soya lecithin :cholesterol. 
In vitro drug diffusion studies
The results indicated, that PNF1 containing span 60 had shown higher drug release profile than other formulations, because niosomes prepared with tweens and other spans were significantly larger than those prepared with Span60. Proniosomes of Span 60 were smaller in size, demonstrated higher hydrophobicity and higher surface area due to low vesicle size and hence better permeability of drug has occured. Higher drug permeation was seen from niosomes prepared with Span 60 than from the other surfactant. This could be due to the emulsification effect of the surfactant after the hydration of the proniosome by the diffusion medium and formation of channels within the gel structure due to loss of lipid bilayer. Drug released from proniosomes prepared with tweens showed lesser extent of drug release compared to that prepared with span. It might be due to the larger size of the vesicles and less lipophilic nature of the Tween, which makes it more difficult for these vesicles to penetrate or fuse with membrane whereas the inclusion of Span which is more lipophilic than Tween further increased the lipophilicity of the drug leading to better penetration.
Formulations which have higher cholesterol content (PNF7-PN12) showed less drug release over a period of 24 hrs. Increase in cholesterol ratio resulted in a more intact lipid bilayers as a barrier for drug release and decreased its leakage by improving the fluidity of the bilayers membrane and reducing its permeability, which led to lower drug elution from the vesicles. 
